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stroke in patients with atrial fibrillation reaches the staggering figure of 25%. 4 Stroke due to atrial fibrillation is also associated with larger cerebral infarcts and a higher neurological impairment. As a consequence, the outcome of patients with atrial fibrillation who suffer a stroke is worse, as they show a greater degree of disability. The risk of stroke in patients with atrial fibrillation increases in the presence of additional factors, such as history of hypertension, diabetes, heart failure, and previous transient ischaemic attack (TIA) or stroke. 5, 6 Recent data also suggest that women with atrial fibrillation have a higher risk of stroke than men, independently of age and additional risk factors. 7 The rate of embolic events originating from the atrium in patients with atrial fibrillation increases with the reduction of left atrial appendix flow velocity and the presence of echocontrast at transoesophageal ultrasound examination. 8 Unfortunately, the duration of atrial fibrillation which may be associated with the development of a thrombus in the atrium is extremely short, as this event may occur within 24 -48 h. As a consequence, even a short episode of atrial fibrillation may significantly increase the thrombogenic substrate and the risk of stroke during the arrhythmic episode, at the time of spontaneous sinus rhythm restoration and also in the following days. A relationship between the number of additional risk factors in patients with atrial fibrillation and the presence of echocontrast or reduced flow velocity in the left atrial appendix has been demonstrated, 9 suggesting that factors such as hypertension, diabetes, and heart failure may influence the complex thromboembolic mechanisms. Antithrombotic therapy prevents stroke in patients with atrial fibrillation. A recently updated meta-analysis 10 which included 29 randomized clinical trials comprising 28 044 patients has shown that oral anticoagulants and antiplatelet agents were significantly effective for both primary and secondary prevention of stroke, with a 64 and 22% reduction of relative risk, respectively. In the 12 trials which compared anticoagulant therapy with antiplatelet agents in 12 963 patients, warfarin was more effective than aspirin, with a relative risk reduction of 39%. It has to be noted that these effects were observed in both permanent and paroxysmal atrial fibrillation. However, the similar efficacy of therapy in the different subtypes of atrial fibrillation is not completely taken into account in clinical practice, as anticoagulants are frequently withdrawn in patients with paroxysmal atrial fibrillation. This choice is usually made because of the apparent absence of recurrence of atrial fibrillation. However, episodes of atrial fibrillation may be completely asymptomatic and go unrecognized, particularly in patients who are treated with antiarrhythmic agents able to maintain a normal heart rate even in the case of recurrence. 12 The incidence of thromboembolic events was similar in patients with paroxysmal atrial fibrillation when compared with those with persistent or permanent atrial fibrillation enrolled in the ACTIVE study (Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events), a trial aimed at comparing warfarin with combined antiplatelet therapy with aspirin and clopidogrel. The risk for thromboembolic events in patients with any type of atrial fibrillation could be significantly lowered with warfarin, which was more effective than the combination of antiplatelet agents. The findings of Nieuwlaat et al. obtained prospectively in a large European population of patients with atrial fibrillation, together with other similar observations, support the recommendation that the type of atrial fibrillation should not influence the choice of appropriate antithrombotic therapy. The choice of antithrombotic therapy should rather be guided by the presence of additional risk factors for stroke. High-risk atrial fibrillation patients show a larger relative risk reduction with oral anticoagulation compared with aspirin, whereas the relative risk reductions are smaller in atrial fibrillation patients with lower stroke rates. The absolute increases in major haemorrhages which may be associated with antithrombotic therapy are small but not negligible. Accordingly, the beneficial effect of oral anticoagulation should be weighed against the risk of bleeding. Thus, quantifying the risk of stroke is crucial for determining which atrial fibrillation patients would benefit most from anticoagulant therapy. Different stroke risk stratification schemes have been proposed for atrial fibrillation patients. 13 In the CHADS 2 score (acronym derived from the individual stroke risk factors: Congestive heart failure, Hypertension, Age .75 years, Diabetes, and prior Stroke or TIA), 2 points are given for prior stroke or TIA, and 1 point is assigned for each of the other factors. Conflict of interest: none declared.
